They’ve downgraded the bottom end of their revenue forecast range by 4% in the space of a month ($180m down to $173m). It seems unlikely they will hit the bottom end of their guidance range they gave a month ago...that’s why you provide a range to give yourself wiggle room and they’re still squirming.
I’m not sure how you can spin this as a positive.
- Forums
- ASX - By Stock
- NXL
- Ann: Nuix Revises FY21 Forecast Range
Ann: Nuix Revises FY21 Forecast Range, page-22
-
-
- There are more pages in this discussion • 198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NXL (ASX) to my watchlist
|
|||||
Last
$3.40 |
Change
-0.100(2.86%) |
Mkt cap ! $1.100B |
Open | High | Low | Value | Volume |
$3.47 | $3.52 | $3.37 | $2.809M | 820.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2881 | $3.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.42 | 3213 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 83 | 3.420 |
1 | 296 | 3.370 |
1 | 6 | 3.340 |
2 | 1501 | 3.330 |
8 | 28294 | 3.300 |
Price($) | Vol. | No. |
---|---|---|
3.240 | 24 | 1 |
3.300 | 1556 | 1 |
3.330 | 1 | 1 |
3.400 | 4063 | 4 |
3.420 | 332 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
NXL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online